tetano
Editor, Senior Moderator
Clin Infect Dis
. 2025 Jul 22;80(Supplement_1):S57-S65.
doi: 10.1093/cid/ciaf095. Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine
Raquel Matavele Chissumba[SUP] 1 2 [/SUP], Gaurav Kwatra[SUP] 3 4 5 [/SUP], Patrícia Ramgi[SUP] 1 [/SUP], Maria Enosse[SUP] 1 [/SUP], Adérito Sigaúque[SUP] 1 [/SUP], Celso Khosa[SUP] 1 [/SUP], Edna Viegas[SUP] 1 [/SUP], Odete Bule[SUP] 1 [/SUP], José Langa[SUP] 1 [/SUP], Nisha Dhar[SUP] 4 [/SUP], Christian Mukendi[SUP] 4 [/SUP], Denise Langa[SUP] 1 [/SUP], Esperança Sevene[SUP] 6 [/SUP], Tandile Hermanus[SUP] 7 8 [/SUP], Nelia Manamela[SUP] 7 8 [/SUP], Simone Richardson[SUP] 7 8 [/SUP], Penny Moore[SUP] 7 8 [/SUP], Shabir Madhi[SUP] 4 [/SUP], Ilesh V Jani[SUP] 1 [/SUP]; SIVCOV study group
Collaborators, Affiliations
Background: More than half of the BBIBP-CorV vaccines, outside of Pacific Asia, were distributed in Africa. Nevertheless, there are limited data on the immunogenicity of BBIBP-CorV from Africa. We compared the antibody response, after 1 and 2 doses of the BBIBP-CorV vaccine, in individuals seropositive or seronegative to severe acute respiratory syndrome coronavirus 2 prior to vaccination.
Methods: From March to May 2021, blood samples were obtained at first and second doses of the BBIBP-CorV, and 2 weeks later. Antibody titers against the full-length spike, receptor binding domain and nucleocapsid protein (anti-NC) of severe acute respiratory syndrome coronavirus 2 were measured. Pseudovirus neutralization assays and antibody-dependent cellular cytotoxicity (ADCC) against the D614G, BA.2, and BA.4 variants were also evaluated.
Results: At the second dose, the immunoglobulin G titers for full-length spike and anti-nucleocapsid protein, the ADCC against BA-2, and the neutralizing activity against the D614G and BA.2 were higher in individuals seropositive to any of the epitopes at the first dose (n = 26) compared to the levels observed 2 weeks later in the seronegative group (n = 25). We did not observe an increase on magnitude of binding antibodies, ADCC, and neutralizing activities, in those seropositive, after the second homologous dose of the BBIBP-CorV vaccine.
Conclusions: We suggest that 1 dose of the BBIBP-CorV vaccine in seropositive individuals induced better antibodies response including against variant of concerns compared to that observed after 2 doses in seronegative individuals. A further homologous dose of the BBIBP-CorV vaccine, in those who are seropositive, does not improve the antibody response observed after the first dose.
Keywords: BBIBP-CorV; COVID-19 vaccine; antibodies; hybrid immunity; inactivated vaccine.
. 2025 Jul 22;80(Supplement_1):S57-S65.
doi: 10.1093/cid/ciaf095. Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine
Raquel Matavele Chissumba[SUP] 1 2 [/SUP], Gaurav Kwatra[SUP] 3 4 5 [/SUP], Patrícia Ramgi[SUP] 1 [/SUP], Maria Enosse[SUP] 1 [/SUP], Adérito Sigaúque[SUP] 1 [/SUP], Celso Khosa[SUP] 1 [/SUP], Edna Viegas[SUP] 1 [/SUP], Odete Bule[SUP] 1 [/SUP], José Langa[SUP] 1 [/SUP], Nisha Dhar[SUP] 4 [/SUP], Christian Mukendi[SUP] 4 [/SUP], Denise Langa[SUP] 1 [/SUP], Esperança Sevene[SUP] 6 [/SUP], Tandile Hermanus[SUP] 7 8 [/SUP], Nelia Manamela[SUP] 7 8 [/SUP], Simone Richardson[SUP] 7 8 [/SUP], Penny Moore[SUP] 7 8 [/SUP], Shabir Madhi[SUP] 4 [/SUP], Ilesh V Jani[SUP] 1 [/SUP]; SIVCOV study group
Collaborators, Affiliations
- PMID: 40694517
- DOI: 10.1093/cid/ciaf095
Background: More than half of the BBIBP-CorV vaccines, outside of Pacific Asia, were distributed in Africa. Nevertheless, there are limited data on the immunogenicity of BBIBP-CorV from Africa. We compared the antibody response, after 1 and 2 doses of the BBIBP-CorV vaccine, in individuals seropositive or seronegative to severe acute respiratory syndrome coronavirus 2 prior to vaccination.
Methods: From March to May 2021, blood samples were obtained at first and second doses of the BBIBP-CorV, and 2 weeks later. Antibody titers against the full-length spike, receptor binding domain and nucleocapsid protein (anti-NC) of severe acute respiratory syndrome coronavirus 2 were measured. Pseudovirus neutralization assays and antibody-dependent cellular cytotoxicity (ADCC) against the D614G, BA.2, and BA.4 variants were also evaluated.
Results: At the second dose, the immunoglobulin G titers for full-length spike and anti-nucleocapsid protein, the ADCC against BA-2, and the neutralizing activity against the D614G and BA.2 were higher in individuals seropositive to any of the epitopes at the first dose (n = 26) compared to the levels observed 2 weeks later in the seronegative group (n = 25). We did not observe an increase on magnitude of binding antibodies, ADCC, and neutralizing activities, in those seropositive, after the second homologous dose of the BBIBP-CorV vaccine.
Conclusions: We suggest that 1 dose of the BBIBP-CorV vaccine in seropositive individuals induced better antibodies response including against variant of concerns compared to that observed after 2 doses in seronegative individuals. A further homologous dose of the BBIBP-CorV vaccine, in those who are seropositive, does not improve the antibody response observed after the first dose.
Keywords: BBIBP-CorV; COVID-19 vaccine; antibodies; hybrid immunity; inactivated vaccine.